ARC Special Research Centre for the Molecular Genetics of Development CMGD
Normal View

CELL PROGRAMMING

 

Rathjen Laboratory - CMGD Adelaide

Telephone: +61 8 8303 5354 or + 61 8 8303 4671

Facsimile: +61 8 8303 5338

Email: peter.rathjen@adelaide.edu.au


Research Focus

Stable pluripotent embryonic stem (ES) cell lines were isolated from the early mouse embryo over 20 years ago. The ability to contribute to all the tissues of the embryo and adult after reintroduction into the embryo, coupled with the ability to differentiate extensively in vitro, has led to the widespread use of these cells as vectors for transmission of genetic alterations into the mouse germline, for modelling embryonic development and as a source of cell populations for experimental analysis. With the isolation of embryonic stem cells from human embryos in 1998, interest in the scientific and commercial application of ES cell technology has increased dramatically. The potential to exploit human ES cells as a source of cell populations with therapeutic applications has led to enormous interest in processes that regulate and control the differentiation of ES cells in vitro. We have been working with mouse ES cells for more than 15 years, developing in vitro differentiation technologies that promote the differentiation of ES cells to specific cell lineages, recapitulating the developmental processes of gastrulation in the early mammalian embryo. These models provide a unique opportunity to identify and characterise differentiation and developmental processes at a cellular and molecular level. Moreover, these differentiation methodologies and the understanding at a molecular level of the regulatory mechanisms will have application to the production of therapeutic agents from human ES cells.

Research Projects

Recent publications

return to top

Lab Members

 

Peter Rathjen Head of the Lab
Lynda Gregory-Badger Laboratory Manager
Rebecca Keough
Senior Research Fellow
Joy Rathjen Senior Research Fellow
Norihisa Shindo
Postdoctoral Fellow
Mr James Hughes PhD Student
Ms Tiffany Liu PhD Student
Ms Sarah To PhD Student


return to top
Australian Collaborators

return to top

Pluripotence in mammalian embryonic stem cells

Pluripotence in mammalian embryonic stem cells: What makes these cells tick?

Pluripotence describes the developmental competence of cells that display a specialised differentiation capability - the ability to give rise, through differentiation, to all cell types of the embryo and adult. Within the mammalian embryo the pluripotent lineage is first apparent as a small population of cells massed to one pole of the expanding blastocyst, the inner cell mass (ICM). Pluripotence persists in cells of the primitive ectoderm, or epiblast, of the pregastrulation embryo, and is lost as somatic cell populations are formed by differentiation. In culture, pluripotence is maintained in embryonic stem (ES) cells, cell lines derived from the ICM of many mammalian species, including mouse or human blastocysts.

Using a conditioned medium, MEDII, and ES cells we have recapitulated the formation of primitive ectoderm in culture. ES cell-derived early primitive ectoderm-like (EPL) cells are pluripotent but differ from ES cells in their gene expression, differentiation potential and response to cytokines. Understanding the signalling molecules required for the formation of EPL cells, and the ability to compare two ontogenetically related pluripotent cell populations has given us a unique window into the processes and pathways that underlie the maintenance and loss of pluripotence. This model has been developed using mouse ES cells and we are currently transferring this knowledge to a human ES cell model.

Signalling pathways required for the formation of EPL cells from ES cells
Characterisation of MEDII has identified L-proline dependent signalling pathway(s) as responsible for the alterations in gene expression and differentiation potential associated with the formation of EPL cells. Inhibition of the transport of proline into the cell, through antagonism of an amino acid transporter, can abrogate the effect of L-proline, suggesting that entry of L-proline into the cell is required for the formation of EPL cells. We are currently screening for downstream effectors of L-proline to gain a complete understanding of the intracellular pathways involved in the formation of EPL cells from ES cells in culture.

Identifying intracellular pathways required for maintaining the transcription of pluripotent regulators in ES cells
Remarkably little is known about links connecting the extracellular environment and the regulation of pluripotence at the level of transcription, the extracellular factors and intracellular signalling pathways that directly regulate the activity of the pluripotent cell transcriptome. The POU-domain transcription factor Oct4 has been recognised for some time as a key regulator of pluripotence: deletion of Oct4 results in a loss of the pluripotent cells within the developing blastocyst. Using a comparative approach based on ES and EPL cells in culture we have initiated projects to understand the signalling pathways that regulate Oct4 within a pluripotent cell.

Epigenetic control of pluripotence and cell commitment
Chromatin structure and composition plays an important role in regulating and maintaining gene expression and cell state. Changes in chromatin are absolutely required for differentiation of ES cells, and also to 'reprogram' differentiated cells to a pluripotent or less differentiated state. Work from our collaborators, the Gilbert laboratory (SUNY), has demonstrated that timing of DNA replication at specific gene loci can change at particular stages of ES cell differentiation, and that this correlates with gene expression changes. This suggests a correlation between changes in gene expression, replication timing and changes in active and inactive chromosomal domains upon loss of pluripotency and commitment to differentiated lineages. However, little is known about how active and silent chromosomal domains are set up early in development and differentiation.

Our work aims to identify changes in chromatin structure (histone modifications, DNA methylation, binding of chromatin modifiers etc), determine the timing of these changes at key points in the differentiation pathway (such as, loss of pluripotency and commitment to a differentiated lineage) and their temporal correlation with gene expression changes. The use of our ES cell differentiation system can provide important temporal information; for example, (i) are new chromatin domains becoming established post-EPL cell stage or during EPL 'maturation', and (ii) are pluripotence genes silenced by sequestration into heterochromatin domains and when does this occur? This approach will also identify co-regulated genes and aid in the elucidation of common regulatory mechanisms that underlie the epigenetic changes.

Understanding the role of CRTR1 in ES cells
CRTR1 is a novel member of the CP2 family of transcription factors with the ability to repress transcription from CP2-responsive genes. CRTR1 was initially identified as differentially expressed between ES and EPL cells in culture: in the embryo CRTR1 is similarly expressed, with transcripts seen in the pluripotent cells of the ICM and down regulated on formation of the primitive ectoderm. CRTR1 is expressed later during development, predominantly in the tubules of the developing kidney where it becomes restricted to the distal convoluted tubules and persists into adulthood. The phenotype of a recently reported CRTR1-/- mouse suggests that the gene product is not essential for the maintenance and differentiation of the pluripotent cells of the early embryo, but is required for normal kidney function.

We are employing two approaches to understanding the role of CRTR1 in pluripotence, molecular characterisation of the protein and identifying target genes. The repression domain of CRTR1 has been mapped to a region encompassing amino acids 48-200. This is consistent with the identified repression domain in LBP9, the human homologue of CRTR1. In heteromeric complexes CRTR1 acts to reduce the activation capability of CP2, thereby repressing the expression of CP2-responsive genes. We are continuing experiments to elucidate the mechanism by which CRTR1 exerts repression. The identification of target genes in ES cells is being undertaken using microarray comparison of cell lines over-expressing either CRTR1 or modified version of the protein capable of transcriptional activation. Potential target genes will be validated by their presence in CRTR1-chromatin fractions.

 

return to top

Lineage-specific differentiation of pluripotent ES cells

Lineage-specific differentiation of pluripotent ES cells: Understanding the molecular cues that regulate differentiation to the primary germ lineages during mammalian gastrulation.

Manipulation of the differentiation environment during EPL cell differentiation results in lineage specific differentiation to either the mesendodermal lineages or ectodermal lineages. In both cases differentiation occurs without the formation of the extraembryonic endodermal lineages.

The formation and differentiation of EPL cells in cell aggregates (suspension culture) in the presence of MEDII (EBMs) results differentiation to the ectodermal lineage and results in a population of neurectoderm. Differentiation within EBMs is homogeneous, synchronous and proceeds via the formation of a number of transient, temporally distinct intermediate populations, providing a unique system to capture and analyse intermediate populations such as pluripotent primitive ectoderm and bipotential definitive ectoderm.

When differentiated as embryoid bodies (EPLEBs) EPL cells form a mixed population of mesoderm and definitive endoderm, analogous with the cell populations that are formed within the primitive streak. In contrast, the differentiated cell products that form during ES cell differentiation within embryoid bodies (EBs) comprise a more diverse array of cell types that include derivatives of the ectodermal lineage and the extraembryonic endoderm lineages. The formation of a more defined set of differentiation products within EPLEBs, coupled with the lack of endogenous signalling that emanates from the extraembryonic endoderm, suggests these bodies provide a superior system for understanding the molecular mechanisms underlying lineage formation and for the formation of cell populations with clinical applications.

Analysis of EPLEBs suggests that differentiation proceeds via a series of defined events that recapitulate the events of the primitive streak in the gastrulating embryo:

  • The patterning of EPL cells to posterior epiblast.
  • An epithelial to mesenchymal transition (EMT) that correlates with cell differentiation and formation of mesendoderm.
  • The differentiation of mesendoderm to mesoderm or endoderm.

By analysing differentiation within EPLEBs, and comparing it to differentiation in EBMs, we are identifying and characterising the signalling molecules and pathways that regulate the developmental outcome of differentiating EPL cells, the decision to form either mesendoderm or ectoderm.

return to top

Deciphering the body's language

Deciphering the body's language: The signalling pathways that lead to positional specification in the neural tube.

Cells within the developing neural tube become specified, or patterned, with respect to the dorsal-ventral and anterior-posterior axes. Patterning of the neural tube and subdivision of the neural progenitors is proposed to underlie the complexity of the mature nervous system. By manipulating the differentiation of EPL cells we can form unpatterned, or naive, neural tube-like cell populations, or neurectoderm, within EBMs, that can be exploited as a model to understand the molecular mechanisms of neural tube patterning.

To recapitulate the processes of cell patterning, ES cell-derived neurectoderm has been exposed to known patterning signals. In response to Sonic hedgehog (SHH) and retinoic acid EPL cell-derived neurectoderm expresses genes specific to the ventral and posterior neural tube, respectively, providing proof-of-concept that these cells can be patterned. The response to these factors appears uniform, with over 90% of the cell population up regulating appropriate gene expression. We are using this system to understand two aspects of positional specification in the neural tube:

Specification of the dorsal/ventral boundary
The interaction of the SHH and BMP4 signalling pathways is proposed to determine the boundary between the dorsal and ventral neural tube, although the mechanism is unclear. By adding varying concentrations of both SHH and BMP4 to unpatterned neurectoderm we can show that BMP4 acts to prevent signalling by SHH and the up regulation of ventrally expressed genes. This has led us to propose a model that predicts the formation of distinct dorsal and ventral domains, whereby BMP4 emanating from the overlying ectoderm prevents ventralisation of the dorsal neural tube by SHH. In contrast, the ventral domain of the neural tube is determined by BMP4 signalling antagonists, emanating from the notochord, which prevent BMP4 antagonism of SHH. o

Identification of novel signalling pathways required for anteriorisation of the neural tube and formation of the forebrain
The signalling pathways that establish anterior identity and underlie the formation of the forebrain are poorly understood. The forebrain is induced from the neural tube by signals emanating from an adjacent organiser, the anterior visceral endoderm (AVE). The AVE expresses Hesx1, a homeobox transcription factor, knock-out of which leads to truncation of the forebrain. We have generated an in vitro 'AVE' by introducing Hesx1 into HepG2 cells (Hesx1:HepG2 cells) and have exposed unpatterned neurectoderm to the resulting conditioned medium. These EBMs demonstrate an anteriorised gene expression, indicated by an induction of forebrain specific marker genes. Microarray analysis of Hesx1:HepG2 has identified a number of candidate signalling molecules that could regulate anteriorisation.

return to top

Publications (since 2000)

Johnson, B.V., Rathjen, J., and Rathjen, P.D. Transcriptional control of pluripotency: decisions in early development. Current Opinion in Genetics & Development (2006), 16:447-454

Kavanagh, S.J., Schulz, T.C., Davey, Pl, Claudianos, C., Russel, C, Rathjen, P.D. (2005) A family of RS domain proteins with novel subcellular localisation and trafficking. Nucleic Acid Research 33: 1309-22

Morris, M.B., Rathjen, J., Keough, R.A., Rathjen, P.D. (2005) Biology of embryonic stem cells. In 'Human Embryonic Stem Cells'. Eds Odorico, J.S., Pederson, R.A., Zhang, S.C. BIOS Scientific Publishers, pp 1-28.

Pralong, D., Lim, M.L., Vassiliev, I., Mrozik, K., Wijesundara, N., Rathjen, P., Verma, P.J. (2005) Tetraploid embryonikc stem cells contribute to the inner cell mass of mouse blastocysts. Cloning and stem cells 7: 272-8

Lang, K.J., Rathjen, J., Vassilieva, S., Rathjen, P.D. (2004) Differentiation of embryonic stem cells to a neural fate: a route to rebuilding the nervous system. Journal of Neuroscience Research 76: 184-92

Rathjen, J.R., Rathjen, P.D. (2004) Embryonic Stem Cells. Isolation and application of pluripotent cells from pregastrulation mammalian embryo in Stem Cell Handbook p.33-43, edited by S. Sell, Humana Press Inc., Totowa, N.J., USA.

Rathjen, J., Washington, J.M., Bettess, M.D., Rathjen, P.D. (2003) Identification of a biological activity that supports maintenance and proliferation of pluripotent cells from the primitive ectoderm of the mouse. Biology of Reproduction 69: 1863-71

Rathjen, J., Rathjen, P.D. (2003) Lineage specific differentiation of mouse ES cells: formation and differentiation of early primitive ectoderm-like (EPL) cells. In Methods in Enzymology, Vol 365: Differentiation of embryonic stem cells pages 3-25, edited by J.N. Abelson and M.I. Simon, Elsevier Academic Press

Pelton, T.A., Sharma, S., Schultz, T.C., Rathjen, J., Rathjen, P.D. (2002) Transient pluripotent cell populations during primitive ectoderm formation: Correlation of in vivo and in vitro pluripotent cell development. Journal of Cell Science 115:329-39

Rathjen, J., Haines, B.P., Hudson, K., Nesci, A., Dunn, S., Rathjen, P.D., (2002) Directed differentiation of pluripotent cells to neural lineages: homogenous formation and differentiation of a neurectoderm population. Development 129:2649-61

Rodda, S.J., Kavanagh, S.J., Rathjen J, Rathjen P.D. (2002) Embryonic stem cell differentiation and the analysis of mammalian development. International Journal of Developmental Biology 46:449-58

Stead, E., White, J., Faast, R., Conn, S., Goldstone, S., Rathjen, J., Dhingra, U., Rathjen, P., Walker D., Dalton, S. (2002) Pluripotent cell division cycles are driven by ectopic Cdk2, cyclin A/E and activities. Oncogene 21: 8320-33

Cui, S., Hope, R.M., Rathjen, J., Voyle, R.B., Rathjen, P.D. (2001). Structure, sequence and function of a marsupial LIF gene: Conservation of IL-6 cytokines. Cytogenet Cell Genet 92: 271-278

Faast, R., Thonglairoam, V., Schulz, T.C., Beall, J., Wells, J.R. E. W., Rathjen, P.D., Tremethick, D.J., Lyons, I. (2001) Histone variant H2AZ is required for early mammalian development. Current Biology 11: 1183-1187

Rathjen, J., Dunn, S., Bettess, M.D., Rathjen, P.D. (2001) Lineage specific differentiation of pluripotent cells in vitro: A role for extraembryonic cell types. Reproduction, Fertility and Development 13: 15-22

Rathjen, J., Haines, B.P., Hudson, K., Nesci, A., Dunn, S., Rathjen, P.D., Directed differentiation of pluripotent cells to neural lineages: homogenous formation and differentiation of a neurectoderm population. Development (in press)

Rathjen, J., Rathjen, P.D. (2001). Mouse ES cells: Experimental exploitation of pluripotent differentiation potential. Current Opinion in Genetics & Development 11: 589-595

Rathjen, J., Rathjen, P.D. (2001) Formation of neural lineages from embryonic stem (ES) cells. The Scientific World (in press)

Rathjen, P.D., Rathjen, J. (2001). Directed differentiation of embryonic stem (ES) cells for therapeutic application. J. Tumor Marker Oncology 16: 112
Rodda, S., Sharma, S., Scherer, M., Chapman, G., Rathjen P. (2001) CRTR-1: A developmentally regulated transcriptional repressor related to the CP2 family of transcription factors. Journal of Biological Chemistry 276: 3324-3332

Whyatt, L.M., Rathjen, P.D. (2001) IFN-inducible mammalian expression systems. Methods in Molecular Biology 2001, 158:301-18
Haines, B.P., Voyle, R.B., Rathjen, P.D. (2000). Intracellular and extracellular Leukaemia Inhibitory Factor proteins have different cellular activities, which are mediated by distinct protein motifs. Molecular Biology Cell 11, 1369 - 1383.

Lake, J., Rathjen, J., Remiszewski, J., Rathjen, P.D. (2000). Reversible reprogramming of pluripotent cell differentiation in vitro. Journal of Cell Science. 113, 555-566.

Rathjen, P.D., Verma, P. (2000). Precision genetic modification of the mammalian genome. In White, D.H., and Walcott, J.J. (eds) (2000). Emerging technologies in Agriculture: From ideas to adoption. Proceedings. Pp 49-58. Bureau of Rural Sciences, Canberra.

Voyle, R.B., Rathjen, P.D. (2000). Regulated expression of alternate transcripts from the mouse Oncostatin M gene: Implications for Interleukin-6 family cytokines. Cytokine 12, 134-141.

Whyatt, L.M., Rathjen, P.D. (2000). IFN-inducible mammalian expression systems. Meth. Mol. Biol. Ed. Tymms, M. and Kola, I. Humana Press.

return to top